DCPH Stock Recent News

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Jen Larson – Senior Vice President-Finance and Investor Relations Steve Hoerter – President and Chief Executive Officer Dan Martin – Chief Commercial Officer Margarida Duarte – Head-International Matt Sherman – Chief Medical Officer Tucker Kelly – Chief Financial Officer Conference Call Participants Daniel Wolle – JP Morgan Nicole Gabreski – Piper Sandler Eun Yang – Jefferies Peter Lawson – Barclays Brad Canino – Stifel Jen Larson Thank you, operator. Welcome, and thank you for joining us today to discuss Deciphera's Third Quarter 2022 Financial Results.

Deciphera (DCPH) reports a narrower-than-expected loss for the third quarter of 2022 while revenues beat estimates. Qinlock drives year-over-year sales.

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 3.51% and 8.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Jazz Pharmaceuticals (JAZZ) have performed compared to their sector so far this year.

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. However, heavy dependence on Qinlock for growth remains a woe.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Jennifer Larson - Senior Vice President, Finance and Investor Relations Steven Hoerter - President and Chief Executive Officer Matthew Sherman - Executive Vice President and Chief Medical Officer Daniel Martin - Senior Vice President and Chief Commercial Officer Margarida Duarte - Senior Vice President and Head of International Tucker Kelly - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Daniel Wolle - JPMorgan Allison Bratzel - Piper Sandler Bradley Canino - Stifel Reni Benjamin - JMP Securities Operator Good day and thank you for standing by. Welcome to the Deciphera Pharmaceuticals' Q2 2022 Conference Call.

Deciphera (DCPH) reports a narrower-than-expected loss in the second quarter of 2022 while revenues beat estimates. Shares rise.

Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.